Improved pulmonary outcomes in surgical patients who receive the drug sugammadex could be due to a more complete reversal of the effects of muscle relaxants used during surgery.
Malaria is a leading killer of children worldwide, and new drugs are needed. New research reports encouraging early clinical results with a new compound.
An instrument currently aboard the International Space Station could grow E.coli bacteria in space, opening a new path to bio-manufacturing drugs during long term space flights.
A map of interactions between the novel coronavirus and human proteins is helping scientists identify drugs that might work as therapeutics.
Two new grant-funding opportunities from the PhRMA Foundation will provide substantial support for young researchers with innovative projects in Drug Discovery and Drug Delivery. Funding of up to $100,000 is available.
A well-known hangover drug not only helps soothe pounding headaches but also triggers profound changes that protect the liver, USC scientists report in new findings that could help prevent alcohol-related harm.
iNO has been used for the treatment of failing lungs, but it was also found to have antiviral properties against coronaviruses.The University of Alabama at Birmingham has been selected to begin enrolling patients in an international study assessing the use of inhaled nitric oxide (iNO) to improve outcomes for COVID-19 patients with severely damaged lungs.
Researchers from Cornell University have identified a possible target for antiviral treatment for COVID-19.
A team of Stony Brook University (SBU) researchers is working on computer models that could help speed the discovery of drugs to combat the novel coronavirus responsible for COVID-19. They are doing this work in collaboration with scientists at the U.S. Department of Energy’s (DOE) Brookhaven National Laboratory and Argonne National Laboratory, and will be leveraging those laboratories’ computational resources and expertise.
Today, the American Thoracic Society announced that Boehringer Ingelheim Pharmaceuticals, Inc., donated $500,000 to support the ATS COVID-19 Crisis Fund, a newly launched initiative to develop and disseminate research, education and scientific recommendations to providers in the pulmonary and critical care communities, as well as other clinicians in need of expanding their skill set during this emergency. Boehringer Ingelheim is the first to make a donation to the Fund.
A team of physician-scientists at Beth Israel Deaconess Medical Center are now enrolling patients in a clinical trial to evaluate a common anti-clotting drug for the treatment of COVID-19-positive patients with ARDS. The newly launched trial follows a special report the team published in the Journal of Trauma and Acute Care Surgery that suggested the use of a drug called tPA could reduce deaths among patients with ARDS as a complication of COVID-19.
Rush University Medical Center is participating in a new clinical trial to test the effectiveness of the drug remdesivir in the treatment of coronavirus disease 2019 (COVID-19).
A new trial led by the Perelman School of Medicine at the University of Pennsylvania will evaluate whether the drug hydroxychloroquine (HCQ) can benefit people infected with COVID-19, as well as whether taking the drug preventatively may help people avoid infection altogether
UCLA Health is one of 75 sites around the globe participating in a clinical trial sponsored by the National Institutes of Health to test the effectiveness of a candidate anti-viral drug against COVID-19.
An international team led by University of British Columbia researcher Dr. Josef Penninger has found a trial drug that effectively blocks the cellular door SARS-CoV-2 uses to infect its hosts.
Rutgers Cancer Institute of New Jersey, a National Cancer Institute-designated Comprehensive Cancer Center, is offering a clinical trial as a potential treatment for patients diagnosed with the coronavirus (COVID-19). The trial, which is not limited to cancer patients is exploring hydroxychloroquine and azithromycin.
Montefiore Health System and Albert Einstein College of Medicine has joined a clinical trial to evaluate the experimental drug remdesivir to treat people who are hospitalized with severe COVID-19 infection.
Announcement from the Harrington Discovery Institute at University Hospitals of a new initiative that galvanizes its transatlantic network of academic institutions, foundations, and philanthropic partners to accelerate promising, near-term therapies to treat COVID-19 and its complications and battle future pandemic threats. In advancing its portfolio of 120 drugs-in-the-making at 54 leading academic centers in North America and the U.K., HDI has developed a proven model that has enabled scientists in academia to accelerate their breakthrough drug discoveries toward trials in patients.
Media are invited to attend and ask questions at this Virtual Press Conference with a Newswise Live Expert Panel to discuss the COVID-19 crisis.
A potential COVID-19 vaccine, delivered by microscopic needles, produces antibodies specific to the virus when tested in mice. This is the first peer-reviewed paper describing a COVID-19 vaccine candidate. The next step is a human clinical trial.
University Hospitals announced it will lead a clinical trial that involves the administration of an investigational drug, ARMS-I, to its caregivers working on the frontlines of the COVID-19 pandemic. The trial, named the ARMS-I COVID Study, is designed to assess whether the drug helps prevent airborne transmission of coronavirus and whether it reduces the symptoms of healthcare providers who have tested positive for the virus.
The University of Illinois at Chicago is participating in two clinical trials for COVID-19 treatments.
Houston Methodist nanomedicine researchers are studying a new drug delivery system that transports oral medication via triglycerides that could eliminate the need for injections or IV treatments of some biologic drugs for rheumatoid arthritis and other autoimmune diseases. They’re doing this with a diabetes drug that resulted in approximately 25% absorption in mice models, considered very high for an oral drug. The research will appear in Science Advances April 1.
Cedars-Sinai has joined an international effort to test an experimental antiviral drug as a potential treatment for COVID-19 (coronavirus). The institution expects to enroll its first clinical trial participant this week.
Individuals taking a class of steroid hormones called glucocorticoids for conditions such as asthma, allergies and arthritis on a routine basis may be unable to mount a normal stress response and are at high risk if they are infected with the virus causing COVID-19, according to a new editorial published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism.
Teprotumumab, the first FDA-approved medicine for thyroid eye disease, provides significant improvement in eye bulging, regardless of patient gender, age or smoking status, according to a study accepted for presentation at ENDO 2020, the Endocrine Society’s annual meeting, and publication in a special supplemental section of the Journal of the Endocrine Society.
Using a research assay called VirScan, scientists plan to study how antibodies from people who have had COVID-19 attack the virus that causes it.
Medical product companies, such as those that make pharmaceuticals and medical devices, make recall decisions quite differently as women are added to their board of directors, according to a new study by professors at four universities, including Indiana University.
Adults who need medical maintenance treatment of the growth hormone disorder acromegaly respond well to an investigational oral form of the drug octreotide, investigators of the Chiasma OPTIMAL study reported. Results of the phase 3 randomized controlled clinical trial were accepted for presentation at ENDO 2020, the Endocrine Society’s annual meeting, and will be published in the Journal of the Endocrine Society.
Two newer types of medications commonly used to treat type 2 diabetes are similar in their ability to reduce major heart complications, including heart attack, stroke and death from cardiovascular disease, according to research accepted for presentation at ENDO 2020, the Endocrine Society’s annual meeting, and publication in a special supplemental section of the Journal of the Endocrine Society.
UC Davis Health physicians and medical staff who treated the first case of community transmission of COVID-19 in the U.S. provide a detailed case study of her condition and the medical steps and challenges they experienced before arriving at a diagnosis and treatment.
Nafamostat mesylate (brand name: Fusan), which is the drug used to treat acute pancreatitis, may effectively block the requisite viral entry process the new coronavirus (SARS-CoV-2) uses to spread and cause disease (COVID-19). The University of Tokyo announced these new findings on March 18, 2020.
The April 2020 issue of the Society of Toxicology’s official journal, Toxicological Sciences, features leading research in toxicology, including several manuscripts covering emerging technologies, methods, and models.
A recent study has found that there is no evidence for or against the use of non-steroidal anti-inflammatory drugs such as ibuprofen for patients with COVID-19.
A multi-site clinical trial, led by the University of Washington School of Medicine in collaboration with New York University Grossman School of Medicine, aims to definitively determine whether hydroxychloroquine can prevent transmission in people exposed to the virus.
Patients with type 1 diabetes who use Medtronic’s MiniMedTM 670G insulin pump system are able to maintain blood glucose levels in the targeted range over 71% of the time, according to a study that analyzed some 6 million days of real-world data. Results of the industry-supported study were accepted for presentation at ENDO 2020, the Endocrine Society’s annual meeting, and will be published in a special supplemental issue of the Journal of the Endocrine Society.
The University of Alabama at Birmingham is launching a collaboration with the biopharmaceutical company Altimmune, Inc. for preclinical testing of a potential vaccine to prevent COVID-19 disease
Some 4,500 Food and Drug Administration-approved drugs and devices are pulled from shelves annually — decisions greatly influenced by the presence of women on a firm’s board, according to new research from the University of Notre Dame.
Argonne scientists are working around the clock to analyze the virus to find new treatments and cures, predict how it will propagate through the population, and make sure that our supply chains remain intact.
Using a free computer game called Foldit, researchers are enlisting the help of citizen scientists to design drugs that could stop the novel coronavirus from infecting human cells.
UC Davis Health has two clinical trials underway for hospitalized patients with severe COVID-19, the disease caused by the novel coronavirus, SARS-CoV-2.
There is no data to suggest that continuing allergy and asthma medications will have any effect on increasing your risk of getting the COVID-19 infection, or if you get the infection, lead to a worse outcome.
University of Colorado Cancer Center group shows CPT1A may be necessary for ovarian cancer spread, chemo-resistance. Moves toward clinical trial of CPT1A inhibitor, etomoxir, against chemo-resistant ovarian cancer.
Removing a gene from the cells that produce insulin prevents mice from developing Type 1 diabetes by sparing the cells an attack from their own immune system, a new UW–Madison study shows.
Researchers say they have found a viable new therapeutic strategy for estrogen receptor-positive (ER+) breast cancer, even cancers that are resistant to current standard of care treatments. Their new preclinical study was accepted for presentation at ENDO 2020, the Endocrine Society’s annual meeting, and publication in a special supplemental section of the Journal of the Endocrine Society.
Scientists have found a way in the laboratory to shorten the time it takes to create a key chemical used to synthesize a variety of medications, fertilizers and other important substances. The finding could make a number of industrial manufacturing processes cheaper and more efficient. And all it takes, essentially, is electrifying an aluminum container that includes the right chemicals.
Researchers in the cancer nanomedicine community debate whether use of tiny structures, called nanoparticles, can best deliver drug therapy to tumors passively — allowing the nanoparticles to diffuse into tumors and become held in place, or actively — adding a targeted anti-cancer molecule to bind to specific cancer cell receptors and, in theory, keep the nanoparticle in the tumor longer. Now, new research on human and mouse tumors in mice by investigators at the Johns Hopkins Kimmel Cancer Center suggests the question is even more complicated.
Chemotherapy has been so unsuccessful against DIPG that researchers have questioned whether chemotherapy drugs are even able to reach the cancer. University of Colorado Cancer Center study shows, "... medicine does reach DIPG tissue in good quantities that have the potential to be effective against the tumor," says lead researcher.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right